HK1215175A1 - 抗-催乳素受體抗體製劑 - Google Patents

抗-催乳素受體抗體製劑

Info

Publication number
HK1215175A1
HK1215175A1 HK16103172.6A HK16103172A HK1215175A1 HK 1215175 A1 HK1215175 A1 HK 1215175A1 HK 16103172 A HK16103172 A HK 16103172A HK 1215175 A1 HK1215175 A1 HK 1215175A1
Authority
HK
Hong Kong
Prior art keywords
receptor antibody
antibody formulations
prolactin receptor
prolactin
formulations
Prior art date
Application number
HK16103172.6A
Other languages
English (en)
Inventor
Xinghang Ma
Jianjie Niu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1215175A1 publication Critical patent/HK1215175A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK16103172.6A 2013-03-15 2016-03-18 抗-催乳素受體抗體製劑 HK1215175A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799629P 2013-03-15 2013-03-15
PCT/US2014/028078 WO2014143909A1 (en) 2013-03-15 2014-03-14 Anti-prolactin receptor antibody formulations

Publications (1)

Publication Number Publication Date
HK1215175A1 true HK1215175A1 (zh) 2016-08-19

Family

ID=50678293

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103172.6A HK1215175A1 (zh) 2013-03-15 2016-03-18 抗-催乳素受體抗體製劑

Country Status (10)

Country Link
US (2) US9023357B2 (zh)
EP (1) EP2968538A1 (zh)
JP (1) JP2016515515A (zh)
CN (1) CN105025925A (zh)
AR (1) AR095496A1 (zh)
CA (1) CA2906101A1 (zh)
HK (1) HK1215175A1 (zh)
TW (1) TW201513882A (zh)
UY (1) UY35460A (zh)
WO (1) WO2014143909A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
MX2018007520A (es) 2015-12-18 2018-08-01 Astellas Pharma Inc Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.
IL249795B (en) * 2016-02-05 2020-01-30 Grifols Worldwide Operations Ltd Intradermal administration of an immunoglobulin preparation g
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
CA3038894A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
RU2756619C2 (ru) * 2017-03-16 2021-10-04 ЭлДжи КЕМ, ЛТД. Жидкая композиция антитела против TNF альфа
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
BR112019017241A2 (pt) * 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
PL3743088T3 (pl) * 2018-01-26 2023-03-20 F. Hoffmann-La Roche Ag Kompozycje i sposoby stosowania il-22 fc
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
EP3927729A4 (en) 2019-02-18 2023-10-11 Eli Lilly and Company THERAPEUTIC ANTIBODY FORMULATION

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2004055164A2 (en) * 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20140033241A (ko) * 2006-08-18 2014-03-17 노바르티스 아게 Ｐｒｌｒ 특이적 항체 및 그 용도
ATE551071T1 (de) * 2006-09-08 2012-04-15 Medimmune Llc Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
EP2109460B1 (en) * 2007-01-11 2016-05-18 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
EP2212432A4 (en) * 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
JP5524967B2 (ja) * 2008-09-19 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 新規抗体処方物
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP2016515515A (ja) * 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤

Also Published As

Publication number Publication date
JP2016515515A (ja) 2016-05-30
US20140271659A1 (en) 2014-09-18
EP2968538A1 (en) 2016-01-20
US9023357B2 (en) 2015-05-05
CA2906101A1 (en) 2014-09-18
UY35460A (es) 2014-10-31
CN105025925A (zh) 2015-11-04
WO2014143909A1 (en) 2014-09-18
AR095496A1 (es) 2015-10-21
TW201513882A (zh) 2015-04-16
US20160002342A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
HK1257261A1 (zh) 抗fcrh5抗體
ZA202005525B (en) Antibody formulations
HK1215175A1 (zh) 抗-催乳素受體抗體製劑
IL244712B (en) Anti- pdl1 antibody compositions
HK1222186A1 (zh) 嵌合抗原受體
HK1207316A1 (zh) 抗催乳素受體抗體製劑
GB201322583D0 (en) Antibodies
HK1220142A1 (zh) 抗體
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
HUE058272T2 (hu) Anti-CCL17 antitestek
GB201312226D0 (en) Improved antibodies
HK1218647A1 (zh) 血管加壓素- 受體激動劑
GB201318283D0 (en) Antibodies